Robot vs. human: can AI plan better prostate cancer radiation?

NCT ID NCT06625034

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase III trial tests whether an automated planning tool called RapidPlan can match or beat human-driven planning for prostate cancer radiation therapy. About 108 men with prostate cancer will be randomly assigned to one of two planning methods. The goal is to see if the automated approach leads to fewer serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Radiation therapy planning software (RapidPlan)
What this could lead to
If successful, this could show that automated planning reduces side effects and saves time compared to manual planning for prostate cancer radiotherapy.
What could go wrong
This is a phase III trial, but it focuses on planning methods, not a new drug or cure. The benefit may be small, and results may not apply to all centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Florida

    NOT_YET_RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.